A comparison of the survival outcome of paclitaxel liposome-based chemoradiotherapy with or without rhEndostatin for unresectable esophageal squamous cell carcinoma: a retrospective study
The addition of rhEndostatin to paclitaxel liposome-based dCRT may improve clinical outcomes for patients with unresectable ESCC while maintaining manageable toxicities. However, further prospective randomized controlled studies are necessary to confirm the survival benefits of this treatment strategy.
Authors
- Shan Huang (ORCID: https://orcid.org/0000-0002-9230-8680)
- Xiaofen Pan (ORCID: https://orcid.org/0000-0002-0773-0976)
- Jiehao Liao
- Junjie Xu (ORCID: https://orcid.org/0000-0003-4303-7295)
- Qun Li (ORCID: https://orcid.org/0000-0002-5501-8262)
- Min Wei (ORCID: https://orcid.org/0000-0002-2649-9271)
- Mengyuan Zhu (ORCID: https://orcid.org/0000-0003-4825-4168)
Institutions
- Sun Yat-sen University (CN)
- The Seventh Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1007/s12672-025-02711-z
- Citations
- 1
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Sun Yat-sen University
- Sun Yat-sen University Cancer Center
- Basic and Applied Basic Research Foundation of Guangdong Province